HCT for Chemorefractory Mantle Cell Lymphoma

This study examined 202 adults with chemotherapy-unresponsive mantle cell lymphoma (MCL) who underwent allogeneic HCT between 1998 and 2010 and whose outcomes were reported to CIBMTR (Center for International Blood and Marrow Transplant Research). Patients received either myeloablative (n=74) or reduced intensity/non-myeloablative conditioning (n=128). Univariate analyses found that intensity of the conditioning regimen had no significant effect on three-year non-relapse mortality, relapse/progression, progression-free survival, and overall survival. Three-year overall survival using myeloablative and reduced intensity/non-myeloablative conditioning was 25% and 30%, respectively (p=0.45). The authors conclude that “despite a refractory disease state, approximately a fourth of MCL patients can attain durable remissions after allo-HCT.”

Hamadani M, et al. Biol Blood Marrow Transplant